CN112533945A - 优化的结合gp41的分子及其用途 - Google Patents

优化的结合gp41的分子及其用途 Download PDF

Info

Publication number
CN112533945A
CN112533945A CN201980048041.9A CN201980048041A CN112533945A CN 112533945 A CN112533945 A CN 112533945A CN 201980048041 A CN201980048041 A CN 201980048041A CN 112533945 A CN112533945 A CN 112533945A
Authority
CN
China
Prior art keywords
domain
binding
molecule
epitope
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048041.9A
Other languages
English (en)
Chinese (zh)
Inventor
郭家颖
君朵·迪瑞希
J·L·诺德斯特姆
刘丽勤
莱斯利·S·约翰逊
S·凯尼格
B·F·海恩斯
G·法拉利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Duke University
Original Assignee
Macrogenics Inc
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Duke University filed Critical Macrogenics Inc
Publication of CN112533945A publication Critical patent/CN112533945A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980048041.9A 2018-05-18 2019-05-13 优化的结合gp41的分子及其用途 Pending CN112533945A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673462P 2018-05-18 2018-05-18
US62/673,462 2018-05-18
PCT/US2019/032030 WO2019222104A1 (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CN112533945A true CN112533945A (zh) 2021-03-19

Family

ID=68540936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048041.9A Pending CN112533945A (zh) 2018-05-18 2019-05-13 优化的结合gp41的分子及其用途

Country Status (12)

Country Link
US (1) US20210246194A1 (https=)
EP (1) EP3794027A4 (https=)
JP (1) JP2021524451A (https=)
CN (1) CN112533945A (https=)
AU (1) AU2019269383A1 (https=)
BR (1) BR112020023432A2 (https=)
CA (1) CA3100398A1 (https=)
IL (1) IL278832A (https=)
MX (1) MX2020012309A (https=)
SG (1) SG11202011355QA (https=)
WO (1) WO2019222104A1 (https=)
ZA (1) ZA202007056B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189561A (zh) * 2013-03-14 2015-12-23 宏观基因有限公司 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
WO2017214092A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy
CN107847591A (zh) * 2015-04-17 2018-03-27 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2015013390A1 (en) * 2013-07-25 2015-01-29 Pincus Seth Anti-hiv dual specificity antibodies and methods of hiv treatment
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP3201227A4 (en) * 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189561A (zh) * 2013-03-14 2015-12-23 宏观基因有限公司 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
CN107847591A (zh) * 2015-04-17 2018-03-27 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
WO2017214092A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARK L CHIU等: "Engineering antibody therapeutics", 《CURRENT OPINION IN STRUCTURAL BIOLOGY》, vol. 38, pages 167 *

Also Published As

Publication number Publication date
BR112020023432A2 (pt) 2021-02-23
MX2020012309A (es) 2021-06-08
SG11202011355QA (en) 2020-12-30
EP3794027A4 (en) 2022-02-09
JP2021524451A (ja) 2021-09-13
IL278832A (en) 2021-01-31
US20210246194A1 (en) 2021-08-12
WO2019222104A1 (en) 2019-11-21
ZA202007056B (en) 2021-10-27
AU2019269383A1 (en) 2020-12-10
EP3794027A1 (en) 2021-03-24
CA3100398A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
KR102364383B1 (ko) 삼중-특이적 결합 분자 및 그것의 사용 방법
TWI773646B (zh) 結合lag-3的分子和其使用方法
JP6955507B2 (ja) Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
TW201730212A (zh) Ｒｏｒ１－結合分子及其使用方法
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
TW202000231A (zh) 變體ｃｄ３-結合結構域及其在用於治療疾病的組合療法中的用途
KR20190099247A (ko) Adam9-결합 분자, 및 이것의 사용 방법
TW201742633A (zh) 使用ＣＤ３２ＢｘＣＤ７９Ｂ結合分子治療炎症性疾病和病症的方法
CN112533945A (zh) 优化的结合gp41的分子及其用途
JP7745556B2 (ja) Ｃｄ１３７結合分子及びその使用
JP7378567B2 (ja) Ｌａｇ‐３結合分子及びその使用方法
HK40092434A (zh) Btla抗体
HK40053460A (en) Tri-specific binding molecules and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210319